Immunogenicity Testing in Human Papillomavirus Virus‐Like‐Particle Vaccine Trials
- 15 July 2009
- journal article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 200 (2), 166-171
- https://doi.org/10.1086/599988
Abstract
No abstract availableThis publication has 27 references indexed in Scilit:
- Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt onlyVaccine, 2006
- Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trialThe Lancet, 2006
- Results of the first WHO international collaborative study on the standardization of the detection of antibodies to human papillomavirusesInternational Journal of Cancer, 2005
- B Lymphocyte Activation by Human Papillomavirus-Like Particles Directly Induces Ig Class Switch Recombination via TLR4-MyD88The Journal of Immunology, 2005
- The papillomavirus life cycleJournal of Clinical Virology, 2005
- Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trialThe Lancet, 2004
- Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18Virology, 2004
- Specific Antibody Levels at the Cervix During the Menstrual Cycle of Women Vaccinated With Human Papillomavirus 16 Virus-Like ParticlesJNCI Journal of the National Cancer Institute, 2003
- On Natural and Artificial VaccinationsAnnual Review of Immunology, 2003
- Simultaneous Quantitation of Antibodies to Neutralizing Epitopes on Virus-Like Particles for Human Papillomavirus Types 6, 11, 16, and 18 by a Multiplexed Luminex AssayClinical and Vaccine Immunology, 2003